

Nivolumab in melanoma: latest evidence and clinical po

Therapeutic Advances in Medical Oncology

7, 97-106

DOI: [10.1177/1758834014567469](https://doi.org/10.1177/1758834014567469)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing. <i>Sensors</i> , 2015, 15, 16281-16313.	2.1	140
2	Current and Emerging Perspectives on Immunotherapy for Melanoma. <i>Seminars in Oncology</i> , 2015, 42, S3-S11.	0.8	19
3	Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 981-993.	1.1	59
4	The current management of brain metastasis in melanoma: a focus on riluzole. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 779-792.	1.4	12
5	Targeting antisense mitochondrial ncRNAs inhibits murine melanoma tumor growth and metastasis through reduction in survival and invasion factors. <i>Oncotarget</i> , 2016, 7, 58331-58350.	0.8	38
6	Immune Checkpoint Blockade Therapy: Merits and Demerits. <i>Journal of Clinical & Experimental Dermatology Research</i> , 2016, 7, .	0.1	0
7	Repurposing Drugs in Oncology (ReDO)â€”diclofenac as an anti-cancer agent. <i>Ecancermedicalscience</i> , 2016, 10, 610.	0.6	80
9	Hydrogen Sulfide Pathway and Cancer. , 2016, , 133-144.		2
10	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. <i>Immunotherapy</i> , 2016, 8, 907-921.	1.0	20
11	A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia. <i>Value in Health</i> , 2016, 19, 1009-1015.	0.1	24
12	Phase II study of proton beam therapy as a nonsurgical approach for mucosal melanoma of the nasal cavity or para-nasal sinuses. <i>Radiotherapy and Oncology</i> , 2016, 118, 267-271.	0.3	36
13	Harnessing the immune system for the treatment of melanoma: current status and future prospects. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 879-893.	1.3	8
14	From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. <i>Drug Discovery Today</i> , 2016, 21, 1027-1036.	3.2	137
15	Pembrolizumab for melanoma- safety profile and future trends. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 727-729.	1.0	9
16	CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy. <i>Tumor Biology</i> , 2016, 37, 13077-13090.	0.8	36
17	Patient-derived tumor xenograft models for melanoma drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 895-906.	2.5	20
18	Immunotherapy in Lung Cancer. <i>Cancer Treatment and Research</i> , 2016, 170, 203-223.	0.2	8
19	Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk. <i>Journal of the Neurological Sciences</i> , 2016, 370, 13-17.	0.3	23

#	ARTICLE	IF	CITATIONS
20	Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. <i>Immunotherapy</i> , 2016, 8, 775-784.	1.0	24
21	Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy. <i>Biotechnology Advances</i> , 2016, 34, 565-577.	6.0	39
22	Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF- κ B, NFAT and AP-1. <i>Journal of Immunological Methods</i> , 2016, 430, 10-20.	0.6	140
23	Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 770-784.	1.9	148
24	Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2016, 18, 21.	1.8	39
25	Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. <i>Clinical Cancer Research</i> , 2016, 22, 886-894.	3.2	705
26	Targeting protein kinase-b3 (akt3) signaling in melanoma. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 273-290.	1.5	16
27	Making Targeted Therapy Compatible with Checkpoint Immunotherapy. <i>Trends in Biotechnology</i> , 2017, 35, 582-584.	4.9	1
28	Current status of research and treatment for non-small cell lung cancer in never-smoking females. <i>Cancer Biology and Therapy</i> , 2017, 18, 359-368.	1.5	66
29	Sensitization of melanoma cells to temozolomide by overexpression of microRNA 203 through direct targeting of glutaminase-mediated glutamine metabolism. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 614-621.	0.6	17
30	Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. <i>Oncology</i> , 2017, 93, 387-394.	0.9	31
31	The Too Many Faces of PD-L1: A Comprehensive Conformational Analysis Study. <i>Biochemistry</i> , 2017, 56, 5428-5439.	1.2	23
32	Radiosynthesis and preclinical PET evaluation of ⁸⁹ Zr-nivolumab (BMS-936558) in healthy non-human primates. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5407-5414.	1.4	72
33	Preclinical Pharmacokinetics and Biodistribution Studies of ⁸⁹ Zr-Labeled Pembrolizumab. <i>Journal of Nuclear Medicine</i> , 2017, 58, 162-168.	2.8	152
34	Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma. <i>Histopathology</i> , 2017, 70, 643-649.	1.6	14
35	Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. <i>Journal of Cancer</i> , 2017, 8, 410-416.	1.2	176
36	New Frontiers in Melanoma Epigenetics—The More We Know, the More We Don't Know. <i>Epigenomes</i> , 2017, 1, 3.	0.8	6
37	Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by <i>Mycobacterium bovis</i> Bacille Calmette-Guérin. <i>Frontiers in Oncology</i> , 2017, 7, 61.	1.3	24

#	ARTICLE	IF	CITATIONS
38	Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-8.	0.5	25
39	PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma. Acta Dermato-Venereologica, 2017, 97, 395-396.	0.6	39
40	Patient-Derived Xenografting of Human Melanoma. , 2017, , 341-363.		0
41	Data-Driven Methods for Advancing Precision Oncology. Current Pharmacology Reports, 2018, 4, 145-156.	1.5	6
42	Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable therapeutic target. Oncoimmunology, 2018, 7, e1452583.	2.1	18
43	The emerging world of breast cancer immunotherapy. Breast, 2018, 37, 200-206.	0.9	39
44	Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis. Clinical Pharmacology and Therapeutics, 2018, 103, 582-590.	2.3	51
45	Mesothelin-targeted second generation CAR T cells inhibit growth of mesothelin-expressing tumors in vivo. Experimental and Therapeutic Medicine, 2019, 17, 739-747.	0.8	21
46	Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. Oncoimmunology, 2018, 7, e1474318.	2.1	30
47	BSA-bioinspired gold nanorods loaded with immunoadjuvant for the treatment of melanoma by combined photothermal therapy and immunotherapy. Nanoscale, 2018, 10, 21640-21647.	2.8	118
48	Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer. Cellular Immunology, 2018, 329, 31-40.	1.4	30
49	Immuno-Oncology: Emerging Targets and Combination Therapies. Frontiers in Oncology, 2018, 8, 315.	1.3	244
50	The Emerging Therapeutic Landscape of Advanced Melanoma. Current Pharmaceutical Design, 2018, 24, 549-558.	0.9	16
51	PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations. International Journal of Molecular Sciences, 2018, 19, 1984.	1.8	31
53	Economics of the Pharmaceutical Industry. Journal of Economic Literature, 2018, 56, 397-449.	4.5	84
54	Medication use evaluation of programmed death-1 inhibitors in a veteran population. Journal of Oncology Pharmacy Practice, 2019, 25, 1066-1075.	0.5	1
55	Circadian Rhythms and Personalized Melanoma Therapy. Europeanization and Globalization, 2019, , 327-340.	0.1	0
56	Personalized Medicine in Healthcare Systems. Europeanization and Globalization, 2019, , .	0.1	2

#	ARTICLE	IF	CITATIONS
57	Effect and biomarker of Nivolumab for non-small-cell lung cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 117, 109199.	2.5	22
58	NK Cell-Fc Receptors Advance Tumor Immunotherapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1667.	1.0	17
59	Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. , 2019, 7, 154.		16
60	A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia. <i>Frontiers in Pharmacology</i> , 2019, 10, 609.	1.6	60
61	Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. <i>International Journal of Cardiology</i> , 2019, 292, 171-179.	0.8	44
62	Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds. <i>Molecular Therapy - Oncolytics</i> , 2019, 13, 93-106.	2.0	107
63	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 453.	2.2	177
64	Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?. <i>Translational Medicine Communications</i> , 2019, 4, .	0.5	3
65	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. <i>Immunotherapy</i> , 2019, 11, 515-529.	1.0	17
66	Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541982709.	0.8	2
67	A STUDY OF METHOD DEVELOPMENT, VALIDATION AND FORCED DEGRADATION FOR SIMULTANEOUS QUANTIFICATION OF CABOZANTINIB AND NIVOLUMAB IN BULK AND PHARMACEUTICAL DOSAGE FORM BY RP-HPLC. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2019, , 102-106.	0.3	1
68	Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody. <i>European Journal of Cancer</i> , 2019, 106, 193-195.	1.3	18
69	Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 53-62.	1.3	7
70	Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold. <i>European Journal of Medicinal Chemistry</i> , 2020, 186, 111856.	2.6	34
71	Oncogenic Tyrosine Phosphatases: Novel Therapeutic Targets for Melanoma Treatment. <i>Cancers</i> , 2020, 12, 2799.	1.7	8
72	Immunotherapy for acute myeloid leukemia: the dawn of a new era?. <i>Annals of Blood</i> , 2020, 5, 13-13.	0.4	0
73	Diagnosis and treatment of melanoma bone metastasis: A multidisciplinary approach. <i>Dermatologic Therapy</i> , 2020, 33, e14193.	0.8	8
74	SAT-LB112 An Unusual Case of Ipilimumab/Nivolumab Induced Fulminant Diabetic Ketoacidosis (DKA) in a Non Diabetic Patient - a Case Report. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	1

#	ARTICLE	IF	CITATIONS
75	Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome. <i>Oncolimmunology</i> , 2020, 9, 1760705.	2.1	11
76	Worsening of anti-Hu paraneoplastic neurological syndrome related to anti-PD-1 treatment: Case report and review of literature. <i>Journal of Neuroimmunology</i> , 2020, 341, 577184.	1.1	27
77	Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making processâ€”A systematic review. <i>Cancer Medicine</i> , 2020, 9, 1603-1612.	1.3	17
78	Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells. <i>Cancers</i> , 2020, 12, 331.	1.7	27
79	Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients. <i>Cancers</i> , 2020, 12, 863.	1.7	18
80	Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1405-1417.	2.0	19
81	Leukemia: Trends in treatment and how close we have achieved eradication. , 2021, , 547-587.		0
82	Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Clinical Science</i> , 2021, 135, 703-724.	1.8	18
83	Programmed cell death 1 as prognostic marker and therapeutic target in upper gastrointestinal cancers. <i>Pathology Research and Practice</i> , 2021, 220, 153390.	1.0	2
84	Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanomaâ€”A Retrospective Multicenter ADOReg Study. <i>Cancers</i> , 2021, 13, 2312.	1.7	11
85	Notch signaling inhibitor and anti-PD-L1 antibody combination therapies decelerate tumor progression in pancreatic cancer. <i>Journal of Pancreatology</i> , 2021, 4, 106-114.	0.3	3
86	MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 2872.	1.0	39
87	Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments. <i>Cancers</i> , 2021, 13, 2858.	1.7	12
88	Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure. <i>World Journal of Gastroenterology</i> , 2021, 27, 2727-2757.	1.4	28
89	Pharmacogenomicâ€”Guided Therapy in Colorectal Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 616-625.	2.3	14
90	Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis. <i>Cancer Cell International</i> , 2021, 21, 426.	1.8	7
91	Cutaneous adverse events caused by immune checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 956-966.	0.6	59
92	Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 664-677.	0.8	7

#	ARTICLE	IF	CITATIONS
93	Immunotherapy of cancer. , 2021, , 141-174.		0
94	Challenges of Immunotherapy. , 2016, , 419-434.		1
96	BSA-modified gold nanorods for combined photothermal therapy and immunotherapy of melanoma. , 2019, , .		3
97	Nanomedicine in Melanoma: Current Trends and Future Perspectives. , 0, , 143-159.		5
98	Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model. <i>Oncotarget</i> , 2016, 7, 76891-76901.	0.8	9
99	Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF<i>V600E</i>-mutant melanoma. <i>Oncotarget</i> , 2018, 9, 10905-10919.	0.8	17
100	BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma. <i>Oncotarget</i> , 2016, 7, 17665-17680.	0.8	13
101	Nivolumab for advanced non-small cell lung cancer: an immunologically-mediated tumor checkout. <i>Annals of Translational Medicine</i> , 2016, 4, 201-201.	0.7	5
102	Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma. <i>International Journal of Critical Illness and Injury Science</i> , 2017, 7, 177.	0.2	13
103	Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 1167-1175.	0.3	51
104	Effect of Gamma Knife Radiosurgery and Programmed Cell Death 1 Receptor Antagonists on Metastatic Melanoma. <i>Cureus</i> , 2017, 9, e1943.	0.2	8
105	Exploring CT Texture Parameters as Predictive and Response Imaging Biomarkers of Survival in Patients With Metastatic Melanoma Treated With PD-1 Inhibitor Nivolumab: A Pilot Study Using a Delta-Radiomics Approach. <i>Frontiers in Oncology</i> , 2021, 11, 704607.	1.3	16
106	New Progress in Breast Cancer Immunotherapy. <i>Advances in Clinical Medicine</i> , 2018, 08, 47-52.	0.0	0
107	Clinicopathological correlation of immune response in human cancers. <i>Oncotarget</i> , 2019, 10, 5859-5870.	0.8	0
108	Pembrolizumab: The Nut Cracker. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 393-396.	0.1	0
109	Nivolumab-Induced Crescentic Immunoglobulin A Nephropathy With Henoch-Schonlein Purpura Features in a Patient Diagnosed With Hepatocellular Carcinoma. <i>Cureus</i> , 2021, 13, e19110.	0.2	1
110	Antibody-drug conjugates: an evolving approach for melanoma treatment. <i>Melanoma Research</i> , 2021, 31, 1-17.	0.6	4
111	Discovery of 4-phenylindolines containing a (5-cyanopyridin-3-yl)methoxy moiety as potent inhibitors of the PD-1/PD-L1 interaction. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 63, 128647.	1.0	4

#	ARTICLE	IF	CITATIONS
113	Vitiligo in a patient with metastatic melanoma receiving human immunoglobulin G4 monoclonal antibody nivolumab treatment. <i>Turkderm</i> , 2022, 56, 135-137.	0.0	0
114	Options of Therapeutics and Novel Delivery Systems of Drugs for the Treatment of Melanoma. <i>Molecular Pharmaceutics</i> , 2022, 19, 4487-4505.	2.3	11
115	A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHolangiocarcinoma (NATCHO). <i>BMC Cancer</i> , 2022, 22, .	1.1	1
116	An <i>in silico</i> model to study the impact of carbonic anhydrase IX expression on tumour growth and anti-PD-1 therapy. <i>Journal of the Royal Society Interface</i> , 2023, 20, .	1.5	2